LeMaitre Vascular (NASDAQ:LMAT) Upgraded to “Strong-Buy” at Zacks Research

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Several other analysts have also weighed in on the stock. Wells Fargo & Company boosted their target price on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the company an “equal weight” rating in a research note on Thursday, February 26th. Citizens Jmp upped their price target on shares of LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 26th. Freedom Capital upgraded shares of LeMaitre Vascular to a “hold” rating in a research report on Tuesday, March 31st. Barrington Research upped their price target on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings upgraded shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, March 10th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $105.80.

LeMaitre Vascular Stock Up 1.9%

LMAT stock opened at $117.39 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. LeMaitre Vascular has a 1-year low of $78.01 and a 1-year high of $118.01. The firm has a fifty day moving average price of $103.02 and a two-hundred day moving average price of $91.82. The firm has a market cap of $2.67 billion, a price-to-earnings ratio of 46.77, a PEG ratio of 3.32 and a beta of 0.67.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm had revenue of $64.45 million during the quarter, compared to analyst estimates of $62.98 million. During the same quarter in the previous year, the firm earned $0.49 earnings per share. The firm’s revenue for the quarter was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Research analysts predict that LeMaitre Vascular will post 1.94 EPS for the current year.

Insider Activity

In other LeMaitre Vascular news, Director David B. Roberts sold 8,464 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 150,000 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the sale, the chief executive officer directly owned 1,532,304 shares of the company’s stock, valued at $163,588,775.04. This represents a 8.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 215,438 shares of company stock worth $23,062,911. Corporate insiders own 9.50% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Hedge funds have recently made changes to their positions in the stock. Cornerstone Planning Group LLC lifted its position in shares of LeMaitre Vascular by 534.0% in the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 283 shares in the last quarter. MAI Capital Management purchased a new stake in shares of LeMaitre Vascular in the third quarter worth approximately $38,000. First Horizon Corp purchased a new stake in shares of LeMaitre Vascular in the third quarter worth approximately $39,000. Geneos Wealth Management Inc. lifted its position in shares of LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares in the last quarter. Finally, EverSource Wealth Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the second quarter worth approximately $47,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.